Genetic and pharmacological evidence that G2019S LRRK2 confers a hyperkinetic phenotype, resistant to motor decline associated with aging

Aging; D1994S knock-in; G2019S knock-in; H-1152; LRRK2; LRRK2 kinase inhibitors; LRRK2 kinase-dead; Nov-LRRK2-11; Parkinson's disease; Ser935 phosphorylation; 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Analysis of Variance; Animals; Brain; Dose-Response Relationship, Drug; Enzyme Inhibitors; Glycine; Humans; Hyperkinesis; Leucine-Rich Repeat Serine-Threonine Protein Kinase-2; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Mutation; NIH 3T3 Cells; Protein-Serine-Threonine Kinases; Serine; Time Factors; Aging; Neurology